Cigna drops GLP-1 obesity drug coverage for its own employees, citing cost

Cigna stopped covering GLP-1 drugs like Wegovy and Zepbound for weight loss for its own U.S. employees starting June 1. The company cited unsustainable costs, with over 10% of its U.S. staff using the medications. This mirrors a broader employer trend of scaling back coverage for high-cost obesity therapies. For practices, this signals tighter payer scrutiny on GLP-1 claims and potential increases in patient out-of-pocket costs for these drugs. Monitor Cigna's public-facing commercial plan policies for similar exclusions; self-funded employer plans may follow Cigna's lead.